A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling
about
Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulatorNeurobiological Insights from mGlu Receptor Allosteric Modulation.Drugs for allosteric sites on receptorsBiased mGlu5-Positive Allosteric Modulators Provide In Vivo Efficacy without Potentiating mGlu5 Modulation of NMDAR CurrentsNovel Allosteric Modulators of G Protein-coupled ReceptorsVU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with In Vivo EfficacyN-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅).Development of allosteric modulators of GPCRs for treatment of CNS disordersOpportunities and challenges in the discovery of allosteric modulators of GPCRs for treating CNS disorders.Molecular Insights into Metabotropic Glutamate Receptor Allosteric ModulationPractical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate ReceptorsProgress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indicationsMetabotropic glutamate receptor subtype 5: molecular pharmacology, allosteric modulation and stimulus biasProgress in novel cognitive enhancers for cognitive aging and Alzheimer's disease.Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP, Long-Term Potentiation, and Disrupts Memory Reconsolidation.The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies.Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia.Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetrationFurther optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compoundMetabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs.mGluR5: exploration of orthosteric and allosteric ligand binding pockets and their applications to drug discovery.Development of 1H-Pyrazolo[3,4-b]pyridines as Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators.Role of mGlu5 Receptors and Inhibitory Neurotransmission in M1 Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia.Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery.Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5.
P2860
Q24338769-8B487F0B-D73D-44EC-A48D-A36206E517BFQ26773431-910B79B1-701E-46B9-AA2F-591A5E6A6656Q27006721-F5616BBC-6F1C-4CF1-A8BA-B89D3AC2A0EBQ27305419-1837A1E7-C673-419B-8BA4-47AF336BC83FQ28081112-68D083A1-D30D-4FCF-B2B8-5C0994B568ECQ30366876-E22174FD-830E-4FB6-AD6A-77123733A68EQ30427199-176FCD6A-6DEA-4C14-A97F-C488C52BBF9EQ30709836-0674F4AC-3162-4D9C-85C2-578378C6F601Q33894613-149BDD91-4BAC-4F80-920D-CD9E51DBCE5CQ34373958-EA8F4914-5D45-4794-BD20-1963F6036A3BQ34399823-9046FD68-343B-4214-9DF8-113C49F035E0Q34468639-7F24A236-E5DC-465C-9E5B-6E83180BD03CQ37183072-AF2D8ED4-A564-489E-BA2E-9DEAA95A0B9AQ38209092-AF275C7C-36F5-4B2B-B4ED-45E88E3575D1Q38567309-DD950C92-3450-4259-A882-5DF91268066AQ38651750-ED6B367C-29C5-4343-9815-EFDF268A27F8Q38700682-39173E9C-D8F6-48BE-9C9E-EDB01E91BA7AQ38863882-21B4243E-4A40-4E9B-AB90-1F8D3DD5671BQ39077987-8201BA9E-F632-4F2E-82AD-02321A1422C6Q39284158-F53A5A23-B376-4F38-8C09-8C6F0FE3A942Q41371056-362047CF-05BC-4138-B510-C4B7D58D4082Q41594414-68A7FBEA-DDB4-4437-AF31-95325D511842Q41870911-257C5CC9-0A71-4421-B558-C68D438FD22AQ44472302-0F19B487-49CB-41A1-BEEF-F98F4F0573E9Q44988763-28E60DDF-1868-4492-9F6D-88490B2806A2Q45793215-6EF8801B-1171-464E-A1D3-A998E89FA50BQ47836225-17B4608F-F325-49D4-8D60-6A30BECA816FQ47865915-86458EAC-07E3-4713-9DB7-34BEDE6DFFB4Q48077200-0F9422AB-91CE-4497-B6B5-E937C9785EFE
P2860
A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A novel metabotropic glutamate ...... imulus bias to mGlu5 signaling
@ast
A novel metabotropic glutamate ...... imulus bias to mGlu5 signaling
@en
type
label
A novel metabotropic glutamate ...... imulus bias to mGlu5 signaling
@ast
A novel metabotropic glutamate ...... imulus bias to mGlu5 signaling
@en
prefLabel
A novel metabotropic glutamate ...... imulus bias to mGlu5 signaling
@ast
A novel metabotropic glutamate ...... imulus bias to mGlu5 signaling
@en
P2093
P2860
P356
P1476
A novel metabotropic glutamate ...... imulus bias to mGlu5 signaling
@en
P2093
C M Niswender
C W Lindsley
M J Noetzel
P N Vinson
S R Stauffer
P2860
P304
P356
10.1124/MOL.112.082891
P577
2013-01-24T00:00:00Z